Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Articles from Emerging Infectious Diseases

Perspective

Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018 [PDF - 1.10 MB - 6 pages]
G. C. Gray et al.

In 2009 and again in 2019, public health warnings were confirmed by the emergence, rapid widespread transmission, and lethality of novel influenza and coronaviruses. The world continues to suffer disease from these respiratory viruses. Two newly recognized emergent respiratory viruses, influenza D and canine coronavirus HuPn-2018, have been shown to have considerable potential for causing future human epidemics, but diagnostics and surveillance for the viruses are lacking. We reviewed data regarding influenza D virus and coronavirus canine coronavirus HuPn-2018. Those data strongly indicate that these viruses are major newly recognized threats. However, little is being done to respond to or prevent disease associated with these viruses, warranting the question of whether we will learn from previous pandemics.

EID Gray GC, Vlasova AN, Lednicky JA, Nguyen-Tien T, Shittu I, Li F. Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018. Emerg Infect Dis. 2026;32(1):1-6. https://doi.org/10.3201/eid3201.251764
AMA Gray GC, Vlasova AN, Lednicky JA, et al. Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018. Emerging Infectious Diseases. 2026;32(1):1-6. doi:10.3201/eid3201.251764.
APA Gray, G. C., Vlasova, A. N., Lednicky, J. A., Nguyen-Tien, T., Shittu, I., & Li, F. (2026). Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018. Emerging Infectious Diseases, 32(1), 1-6. https://doi.org/10.3201/eid3201.251764.
Synopses

Pulmonary Histoplasmosis, Taiwan, 1997–2024 [PDF - 1.33 MB - 8 pages]
T. Kao et al.

Pulmonary histoplasmosis has traditionally been considered geographically restricted to disease-endemic regions. Taiwan, historically nonendemic, has recently witnessed rising infections. We conducted a retrospective study by reviewing adult patients in Taiwan who had pathologically confirmed pulmonary histoplasmosis during June 1997–December 2024. We analyzed 14 cases with lung involvement. Eight case-patients were male and 6 female; mean age was 56.6 years. Of note, 11 case-patients (78.6%) had no history of travel to histoplasmosis-endemic regions; 10 (71.4%) were immunocompetent. Left upper lobe involvement was most common (n = 4 [28.6%]), with nodular lesions predominating (n = 12 [85.7%]). Most (11 [78.6%]) patients received antifungal therapy, mostly with voriconazole. Outcomes were favorable; 1 (7.1%) patient died. Two additional case-patients without lung involvement exhibited similar demographics and clinical outcomes. Case identification rate has increased since 2015. This 27-year study documents the emergence of pulmonary histoplasmosis in Taiwan, emphasizing the need for heightened clinical suspicion in nonendemic regions.

EID Kao T, Yang S, Hu H, Huang Y, Shu C, Sheng W. Pulmonary Histoplasmosis, Taiwan, 1997–2024. Emerg Infect Dis. 2026;32(1):7-14. https://doi.org/10.3201/eid3201.251091
AMA Kao T, Yang S, Hu H, et al. Pulmonary Histoplasmosis, Taiwan, 1997–2024. Emerging Infectious Diseases. 2026;32(1):7-14. doi:10.3201/eid3201.251091.
APA Kao, T., Yang, S., Hu, H., Huang, Y., Shu, C., & Sheng, W. (2026). Pulmonary Histoplasmosis, Taiwan, 1997–2024. Emerging Infectious Diseases, 32(1), 7-14. https://doi.org/10.3201/eid3201.251091.

Medscape CME Activity
Retrospective Case Series of Ocular Lyme Disease, 1988–2025 [PDF - 1.95 MB - 6 pages]
J. Bellafiore et al.

Reports of ocular manifestations of Lyme disease (LD) are uncommon, and signs and symptoms may be overlooked by physicians. We conducted a retrospective case series of ocular LD reported during 1988–2025. Among 27 published reports in PubMed, we noted that, in 38 cases, the most common ocular manifestation was uveitis, representing 45% of cases, followed by optic neuritis and cranial nerve palsies (including trochlear and abducens). Not all cases met Centers for Disease Control and Prevention surveillance guidelines for LD, given that some case reports were published before the current guidelines. Cases that provided microbiologic proof were 2 anterior uveitis cases, 1 case of anterior uveitis with abducens’s nerve palsy, 1 case of intermediate uveitis, and 1 case of intranuclear ophthalmoplegia. Ocular LD can have a broad variety of manifestations; therefore, physicians should be aware of those manifestations and obtain microbiologic proof for a more definitive diagnosis and epidemiologic value when possible.

EID Bellafiore J, Mahrous A, Gurumurthy V, Capitle E, Schutzer SE. Retrospective Case Series of Ocular Lyme Disease, 1988–2025. Emerg Infect Dis. 2026;32(1):15-20. https://doi.org/10.3201/eid3201.250769
AMA Bellafiore J, Mahrous A, Gurumurthy V, et al. Retrospective Case Series of Ocular Lyme Disease, 1988–2025. Emerging Infectious Diseases. 2026;32(1):15-20. doi:10.3201/eid3201.250769.
APA Bellafiore, J., Mahrous, A., Gurumurthy, V., Capitle, E., & Schutzer, S. E. (2026). Retrospective Case Series of Ocular Lyme Disease, 1988–2025. Emerging Infectious Diseases, 32(1), 15-20. https://doi.org/10.3201/eid3201.250769.

Two Cases of Q Fever in Pregnancy, including Management of the Newborn, Australia [PDF - 489 KB - 7 pages]
R. Silcock et al.

Optimal management of the birthing parent with Q fever in pregnancy and of the infant has not been established. Coxiella burnetii expresses a tropism for the placenta; resulting infection can potentially lead to spontaneous abortion and fetal demise. Although evidence around preventing transmission and infection in the peripartum and postpartum period is lacking, reports of healthy babies born to mothers with acute or chronic Q fever in pregnancy are increasing. Historically, many clinicians have recommended against breastfeeding in this setting because of a theoretical risk for bacterial transmission through breastmilk. We discuss 2 women in Australia who had Q fever in pregnancy, focusing on the peripartum period and infant management. Breastfeeding was encouraged in both cases. Both infants were born healthy and at term and have demonstrated no serologic or clinical evidence of Q fever infection in the first year of life.

EID Silcock R, Horvath R, Chew S, Nourse C. Two Cases of Q Fever in Pregnancy, including Management of the Newborn, Australia. Emerg Infect Dis. 2026;32(1):21-27. https://doi.org/10.3201/eid3201.251048
AMA Silcock R, Horvath R, Chew S, et al. Two Cases of Q Fever in Pregnancy, including Management of the Newborn, Australia. Emerging Infectious Diseases. 2026;32(1):21-27. doi:10.3201/eid3201.251048.
APA Silcock, R., Horvath, R., Chew, S., & Nourse, C. (2026). Two Cases of Q Fever in Pregnancy, including Management of the Newborn, Australia. Emerging Infectious Diseases, 32(1), 21-27. https://doi.org/10.3201/eid3201.251048.

Case Series of Bacteremia Associated with Probiotic Use in Children after Cardiac Surgery, China [PDF - 424 KB - 6 pages]
X. Wang et al.

We examined probiotic-associated bacteremia in a cohort of postoperative pediatric cardiac surgery patients in China. Among 16,436 children who underwent cardiac surgery during 2019–2024, a total of 5,034 received probiotics; 6 developed bacteremia with probiotic strains (Bacillus subtilis, Bacillus licheniformis, Lacticaseibacillus rhamnosus). Three cases occurred in children who had not directly received probiotics, suggesting potential cross-contamination or catheter-related transmission. All 6 patients had complex congenital heart disease and central venous catheters; 5 underwent palliative surgery. Fever, elevated C-reactive protein and leukocytes, and use of respiratory support were common. Antibiotic therapy achieved blood-culture clearance in all; 1 death occurred because of underlying cardiac disease, not infection. Our findings conclude probiotic-associated bacteremia is rare and usually resolves with antibiotics; outcomes correlate more with cardiac complexity than bacteremia itself. Maintaining perioperative probiotic use and enhancing infection-control measures, specifically regarding central line care, are recommended to minimize the risk for probiotic-associated bacteremia in pediatric cardiosurgical patients.

EID Wang X, Li S, Huo D, Li C, Zhang Q, Wang X. Case Series of Bacteremia Associated with Probiotic Use in Children after Cardiac Surgery, China. Emerg Infect Dis. 2026;32(1):28-33. https://doi.org/10.3201/eid3201.250298
AMA Wang X, Li S, Huo D, et al. Case Series of Bacteremia Associated with Probiotic Use in Children after Cardiac Surgery, China. Emerging Infectious Diseases. 2026;32(1):28-33. doi:10.3201/eid3201.250298.
APA Wang, X., Li, S., Huo, D., Li, C., Zhang, Q., & Wang, X. (2026). Case Series of Bacteremia Associated with Probiotic Use in Children after Cardiac Surgery, China. Emerging Infectious Diseases, 32(1), 28-33. https://doi.org/10.3201/eid3201.250298.
Research

Medscape CME Activity
Group A Streptococcus Meningitis, United States, 1997–2022 [PDF - 1.23 MB - 11 pages]
P. A. Hawkins et al.

Group A Streptococcus (GAS) causes a variety of diseases in humans but is not widely appreciated as a cause of meningitis. During 1997–2022, ten sites participating in the Active Bacterial Core Surveillance network in the United States identified GAS meningitis cases. We calculated annual incidence and case-fatality rates (CFRs) for 320 of those cases and determined antimicrobial resistance by whole-genome sequencing. Annual incidence of GAS meningitis ranged from 0.02 to 0.07 cases/100,000 persons. Children <1 year of age had the highest average annual incidence, 0.23 cases/100,000 children. GAS meningitis had a higher CFR (19.4%) than meningitis caused by group B Streptococcus, Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae. Clindamycin resistance among GAS meningitis isolates increased from 3.2% during 1997–2002 to 17.7% during 2018–2022. Clinicians should be aware that meningitis is an uncommon but severe manifestation of invasive GAS and has a higher CFR than more established meningitis etiologies.

EID Hawkins PA, Chochua S, Prasad N, Okaro JO, Li Y, Martin T, et al. Group A Streptococcus Meningitis, United States, 1997–2022. Emerg Infect Dis. 2026;32(1):29-39. https://doi.org/10.3201/eid3201.250871
AMA Hawkins PA, Chochua S, Prasad N, et al. Group A Streptococcus Meningitis, United States, 1997–2022. Emerging Infectious Diseases. 2026;32(1):29-39. doi:10.3201/eid3201.250871.
APA Hawkins, P. A., Chochua, S., Prasad, N., Okaro, J. O., Li, Y., Martin, T....Gregory, C. J. (2026). Group A Streptococcus Meningitis, United States, 1997–2022. Emerging Infectious Diseases, 32(1), 29-39. https://doi.org/10.3201/eid3201.250871.

Reduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024–25 [PDF - 2.89 MB - 10 pages]
S. Villa et al.

During the 2024–25 winter season, a universal immunization campaign with nirsevimab was implemented in a region of Italy to prevent respiratory syncytial virus (RSV) infection among infants <12 months of age. We assessed its effects using regional syndromic surveillance data on emergency department visits (EDVs) and hospitalizations for lower respiratory tract infections and RSV infections. We estimated expected burden using an interrupted time series analysis, based on historical trends, and observed values with predictions. Children 1–5 years of age, not eligible for immunization, served as a comparison group. Among infants, EDVs for acute lower respiratory tract infections decreased by 42.7% and hospitalizations decreased by 46.5%, whereas EDVs for RSV infection decreased by 49.3% and hospitalizations decreased by 55.0%. No reductions were observed in children 1–5 years of age, confirming ongoing RSV circulation. Our findings support the effectiveness of universal nirsevimab immunization in reducing severe RSV-related outcomes among infants.

EID Villa S, Scarioni S, Pigozzi E, Maffeo M, Maistrello M, Bagarella G, et al. Reduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024–25. Emerg Infect Dis. 2026;32(1):45-54. https://doi.org/10.3201/eid3201.250870
AMA Villa S, Scarioni S, Pigozzi E, et al. Reduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024–25. Emerging Infectious Diseases. 2026;32(1):45-54. doi:10.3201/eid3201.250870.
APA Villa, S., Scarioni, S., Pigozzi, E., Maffeo, M., Maistrello, M., Bagarella, G....Cereda, D. (2026). Reduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024–25. Emerging Infectious Diseases, 32(1), 45-54. https://doi.org/10.3201/eid3201.250870.

Genomic Insights into Marburg Virus Strains from 2023 and 2025 Outbreaks in Kagera, Tanzania [PDF - 2.36 MB - 8 pages]
L. A. Mapunda et al.

Marburg virus (MARV) is the primary cause of Marburg virus disease (MVD), a severe hemorrhagic fever with a high case-fatality rate. The first reported MVD outbreak in Tanzania occurred in 2023, followed by a second outbreak in 2025, both within the Kagera region. During those MVD outbreaks, 174 suspected cases were identified; of those, 10 were laboratory confirmed. After complete genome assembly and bioinformatic analyses, we found the MARV strains of the 2023 and 2025 outbreaks to be closely related and clustered with MARV strains that caused outbreaks in Rwanda (2024) and Uganda (2014). The sequences from both MVD outbreaks in Tanzania showed >99.71% nucleotide identity, suggesting a possible single spillover event followed by limited human-to-human virus transmission. Further ecologic studies are essential to identify potential spillover events, but our findings indicate that closely related MARV strains circulate in Kagera, Tanzania, posing a risk for future outbreak recurrence.

EID Mapunda LA, Beyanga M, Moremi N, Hakizimana JN, Kamori D, Chacha A, et al. Genomic Insights into Marburg Virus Strains from 2023 and 2025 Outbreaks in Kagera, Tanzania. Emerg Infect Dis. 2026;32(1):55-62. https://doi.org/10.3201/eid3201.251314
AMA Mapunda LA, Beyanga M, Moremi N, et al. Genomic Insights into Marburg Virus Strains from 2023 and 2025 Outbreaks in Kagera, Tanzania. Emerging Infectious Diseases. 2026;32(1):55-62. doi:10.3201/eid3201.251314.
APA Mapunda, L. A., Beyanga, M., Moremi, N., Hakizimana, J. N., Kamori, D., Chacha, A....Magembe, G. (2026). Genomic Insights into Marburg Virus Strains from 2023 and 2025 Outbreaks in Kagera, Tanzania. Emerging Infectious Diseases, 32(1), 55-62. https://doi.org/10.3201/eid3201.251314.

Emergence of New Delhi Metallo-β-Lactamase 14–Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands [PDF - 2.59 MB - 11 pages]
P. Aja-Macaya et al.

The emergence of a high-risk New Delhi metallo-β-lactamase 14–producing Klebsiella pneumoniae sequence type 147 clone is of public health concern because of its rapid international spread. We report cross-border emergence and rapid dissemination of that clone in the Canary Islands, Spain, during 2023–2025. We analyzed 30 isolates recovered during 2023 in detail by reviewing clinical and epidemiologic data, conducting whole-genome sequencing to assess clonal relatedness and analyze resistomes, and performing antimicrobial susceptibility testing of novel therapeutic options through reference broth microdilution. The isolates formed a well-defined cluster, with minimal genomic distance and identical resistomes, confirming the local outbreak. Those clones were also closely related to other international New Delhi metallo-β-lactamase 14–producing K. pneumoniae sequence type 147 isolates, supporting the ongoing cross-border expansion of that clone. Aztreonam/avibactam was the most active therapeutic option (MICs <0.125 mg/L). Our findings highlight the need for close monitoring to prevent further dissemination of this clone.

EID Aja-Macaya P, Blanco-Martín T, Mateo-León C, del Rosario-Quintana C, Piña C, de la Cruz-Tabares E, et al. Emergence of New Delhi Metallo-β-Lactamase 14–Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands. Emerg Infect Dis. 2026;32(1):63-73. https://doi.org/10.3201/eid3201.251504
AMA Aja-Macaya P, Blanco-Martín T, Mateo-León C, et al. Emergence of New Delhi Metallo-β-Lactamase 14–Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands. Emerging Infectious Diseases. 2026;32(1):63-73. doi:10.3201/eid3201.251504.
APA Aja-Macaya, P., Blanco-Martín, T., Mateo-León, C., del Rosario-Quintana, C., Piña, C., de la Cruz-Tabares, E....Arca-Suárez, J. (2026). Emergence of New Delhi Metallo-β-Lactamase 14–Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands. Emerging Infectious Diseases, 32(1), 63-73. https://doi.org/10.3201/eid3201.251504.

Effect of Chloramine Disinfection of Community Water System on Legionnaires’ Disease Outbreak, Minnesota, USA, 2024 [PDF - 858 KB - 8 pages]
M. E. Bledsoe et al.

The Minnesota Department of Health identified an outbreak of Legionnaires’ disease in a city in northern Minnesota, USA, in April 2023 that continued until chloramine disinfection of the community water system was implemented. Before chloramine disinfection was implemented, Legionella pneumophila was detected in 1 of 16 samples from the drinking water distribution system and in 5 of 10 premise plumbing samples using both cultivation-dependent (Legiolert) and cultivation-independent (digital PCR) assays in this independent investigation. Approximately 11 weeks after disinfection was implemented, all distribution system samples tested negative; however, 1 of 6 Legiolert-tested and 3 of 6 digital PCR–tested premise plumbing samples were positive. After 24 weeks of disinfection, all samples collected from the distribution system and premise plumbing tested negative. Our results show that a community water system supplied by groundwater supported substantial growth of L. pneumophila in premise plumbing and that chloramine disinfection halted the outbreak.

EID Bledsoe ME, Goel A, Adelgren M, LaPara TM, Hozalski RM. Effect of Chloramine Disinfection of Community Water System on Legionnaires’ Disease Outbreak, Minnesota, USA, 2024. Emerg Infect Dis. 2026;32(1):74-81. https://doi.org/10.3201/eid3201.251232
AMA Bledsoe ME, Goel A, Adelgren M, et al. Effect of Chloramine Disinfection of Community Water System on Legionnaires’ Disease Outbreak, Minnesota, USA, 2024. Emerging Infectious Diseases. 2026;32(1):74-81. doi:10.3201/eid3201.251232.
APA Bledsoe, M. E., Goel, A., Adelgren, M., LaPara, T. M., & Hozalski, R. M. (2026). Effect of Chloramine Disinfection of Community Water System on Legionnaires’ Disease Outbreak, Minnesota, USA, 2024. Emerging Infectious Diseases, 32(1), 74-81. https://doi.org/10.3201/eid3201.251232.

Detection of Novel Thermotolerant Tepidimonas sp. Bacteria in Human Respiratory Specimens, Hong Kong, China, 2024 [PDF - 1.71 MB - 11 pages]
K. Chiu et al.

In patients with acute respiratory infections (ARIs), routine diagnostic tests often fail to identify the microbial cause; thus, many ARIs have undetermined etiology. We investigated potential involvement of thermotolerant bacteria in ARIs among patients in Hong Kong, China, by incubating blood agar inoculated with respiratory specimens at 50°C for 5 days. Among 7,257 specimens analyzed, 58 specimens from 57 patients grew thermotolerant bacteria not identified by other methods. We identified Tepidimonas spp. in 42 isolates, 3 of which appear to be a novel Tepidimonas species (tentatively Tepidimonas hongkongensis sp. nov). Genomic analysis revealed various virulence, resistance, and stress-related genomes in the 3 isolates. Tepidimonas spp. bacteria were predominantly isolated from patients with chronic lung disease and malignancies. We also detected T. hongkongensis in hospital water samples but at a lower percentage than in respiratory specimens, suggesting colonization potential. Clinical implications of T. hongkongensis remain unknown; continued surveillance could determine its role in ARIs.

EID Chiu K, Wong S, Chiu E, Man Ng R, Chen J, Fong J, et al. Detection of Novel Thermotolerant Tepidimonas sp. Bacteria in Human Respiratory Specimens, Hong Kong, China, 2024. Emerg Infect Dis. 2026;32(1):82-92. https://doi.org/10.3201/eid3201.250818
AMA Chiu K, Wong S, Chiu E, et al. Detection of Novel Thermotolerant Tepidimonas sp. Bacteria in Human Respiratory Specimens, Hong Kong, China, 2024. Emerging Infectious Diseases. 2026;32(1):82-92. doi:10.3201/eid3201.250818.
APA Chiu, K., Wong, S., Chiu, E., Man Ng, R., Chen, J., Fong, J....Teng, J. (2026). Detection of Novel Thermotolerant Tepidimonas sp. Bacteria in Human Respiratory Specimens, Hong Kong, China, 2024. Emerging Infectious Diseases, 32(1), 82-92. https://doi.org/10.3201/eid3201.250818.

Clinical Manifestations of Emerging Trichosporon spp. Infections, France [PDF - 1.96 MB - 10 pages]
M. Desnos-Ollivier et al.

Fungi in the family Trichosporonaceae are rarely involved in invasive disease but are frequently associated with colonization or respiratory allergic infection. Trichosporonaceae exhibit intrinsic resistance to echinocandin antimicrobial drugs, posing challenges for treatment and contributing to high mortality rates. We complied a nationwide analysis of 112 cases of invasive disease caused by Trichosporon spp. and related fungi, diagnosed in France over 20 years, that combined clinical data, susceptibility profiles, and molecular identification. We identified 12 species; T. asahii was the most common species recovered, and the new species T. austroamericanum was next. Comparison of clinical data highlighted species and genotypic differences, such as a much higher proportion of children infected by T. asahii and major differences in antimicrobial drug susceptibility. Correct identification is not only of epidemiologic interest but also necessary for patient management because of the varying clinical and microbiological characteristics found in different species.

EID Desnos-Ollivier M, Alanio A, Gits-Muselli M, Boukris-Sitbon K, Bertho A, Sturny-Leclère A, et al. Clinical Manifestations of Emerging Trichosporon spp. Infections, France. Emerg Infect Dis. 2026;32(1):93-102. https://doi.org/10.3201/eid3201.250504
AMA Desnos-Ollivier M, Alanio A, Gits-Muselli M, et al. Clinical Manifestations of Emerging Trichosporon spp. Infections, France. Emerging Infectious Diseases. 2026;32(1):93-102. doi:10.3201/eid3201.250504.
APA Desnos-Ollivier, M., Alanio, A., Gits-Muselli, M., Boukris-Sitbon, K., Bertho, A., Sturny-Leclère, A....Lanternier, F. (2026). Clinical Manifestations of Emerging Trichosporon spp. Infections, France. Emerging Infectious Diseases, 32(1), 93-102. https://doi.org/10.3201/eid3201.250504.

Enhanced Isolation and Detection of COVID-19 in Hospitalized Patients Undergoing Antiviral Therapy [PDF - 2.96 MB - 11 pages]
R. Perera et al.

We evaluated the efficiency of SARS-CoV-2 detection from patient respiratory specimens by comparing 3 cell lines: Vero E6, Vero E6 expressing transmembrane protease serine 2 (Vero E6 T2), and Vero E6 expressing angiotensin-converting enzyme 2 and transmembrane protease serine 2 (Vero E6 A2T2). We compared a range of sample types, clinical conditions, and real-time reverse transcription PCR cycle threshold values. Vero E6 A2T2 exhibited enhanced sensitivity by supporting efficient virus entry and replication with faster cytopathic effect. Vero E6 culture isolated infectious virus only up to 3 days after PCR confirmation but with Vero E6 A2T2 cells, culture occurred up to 7 days after confirmation. Whole-genome sequencing showed no evidence of adaptive mutations when Vero E6 A2T2 was used for viral culture, supporting use for downstream analyses. Optimized infectious virus detection systems are needed for research and clinical settings, particularly for high-risk, immunocompromised populations that produce virus longer and contribute to variant emergence.

EID Perera R, Marques A, Graham-Wooten J, Tan L, Cohen N, Rodino K, et al. Enhanced Isolation and Detection of COVID-19 in Hospitalized Patients Undergoing Antiviral Therapy. Emerg Infect Dis. 2026;32(1):103-113. https://doi.org/10.3201/eid3201.251011
AMA Perera R, Marques A, Graham-Wooten J, et al. Enhanced Isolation and Detection of COVID-19 in Hospitalized Patients Undergoing Antiviral Therapy. Emerging Infectious Diseases. 2026;32(1):103-113. doi:10.3201/eid3201.251011.
APA Perera, R., Marques, A., Graham-Wooten, J., Tan, L., Cohen, N., Rodino, K....Weiss, S. R. (2026). Enhanced Isolation and Detection of COVID-19 in Hospitalized Patients Undergoing Antiviral Therapy. Emerging Infectious Diseases, 32(1), 103-113. https://doi.org/10.3201/eid3201.251011.
Dispatches

Detection of Oropouche and Punta Toro Virus Infections by Enhanced Surveillance, Panama, 2023–2024 [PDF - 674 KB - 4 pages]
M. Chen-Germán et al.

Enhanced arboviral surveillance in Panama revealed an Oropouche virus case, 5 months before the 2025 national outbreak, in samples that tested negative for routinely screened arboviruses. Subsequent contact tracing identified an additional case of Punta Toro virus. Our findings highlight the importance of expanding diagnostic efforts to identify circulating arboviruses.

EID Chen-Germán M, González C, Araúz D, Aguilar C, Vega M, Chavarria O, et al. Detection of Oropouche and Punta Toro Virus Infections by Enhanced Surveillance, Panama, 2023–2024. Emerg Infect Dis. 2026;32(1):114-117. https://doi.org/10.3201/eid3201.251224
AMA Chen-Germán M, González C, Araúz D, et al. Detection of Oropouche and Punta Toro Virus Infections by Enhanced Surveillance, Panama, 2023–2024. Emerging Infectious Diseases. 2026;32(1):114-117. doi:10.3201/eid3201.251224.
APA Chen-Germán, M., González, C., Araúz, D., Aguilar, C., Vega, M., Chavarria, O....Moreno, B. (2026). Detection of Oropouche and Punta Toro Virus Infections by Enhanced Surveillance, Panama, 2023–2024. Emerging Infectious Diseases, 32(1), 114-117. https://doi.org/10.3201/eid3201.251224.

Sphingobacterium hotanense Infections in Immunocompromised Patients, United States [PDF - 1.05 MB - 4 pages]
K. Abu-Zeinah et al.

Sphingobacterium hotanense is a gram-negative bacillus identified in 2013 from soil samples that rarely causes infection in humans. We describe 2 cases of S. hotanense bacteremia secondary to skin and soft tissue infection in immunocompromised patients in Minnesota, USA, highlighting S. hotanense as a potential pathogen in immunocompromised hosts with environmental exposure.

EID Abu-Zeinah K, Lueck BD, Fuentes SA, Puumala E, Abu Saleh OM. Sphingobacterium hotanense Infections in Immunocompromised Patients, United States. Emerg Infect Dis. 2026;32(1):118-121. https://doi.org/10.3201/eid3201.251290
AMA Abu-Zeinah K, Lueck BD, Fuentes SA, et al. Sphingobacterium hotanense Infections in Immunocompromised Patients, United States. Emerging Infectious Diseases. 2026;32(1):118-121. doi:10.3201/eid3201.251290.
APA Abu-Zeinah, K., Lueck, B. D., Fuentes, S. A., Puumala, E., & Abu Saleh, O. M. (2026). Sphingobacterium hotanense Infections in Immunocompromised Patients, United States. Emerging Infectious Diseases, 32(1), 118-121. https://doi.org/10.3201/eid3201.251290.

Dermacentor occidentalis Ticks and Link to Rickettsia lanei Infections, California, USA [PDF - 786 KB - 4 pages]
W. S. Probert et al.

Rickettsia lanei is a newly recognized spotted fever group rickettsial species that causes severe Rocky Mountain spotted fever–like illness. We used genome sequencing, enabled by hybridization capture-based target enrichment, to establish Dermacentor occidentalis ticks as the likely source of a human infection with R. lanei in California, USA.

EID Probert WS, Kath C, Putirka N, Saunders M, Bermudez B, Cazas MI, et al. Dermacentor occidentalis Ticks and Link to Rickettsia lanei Infections, California, USA. Emerg Infect Dis. 2026;32(1):122-125. https://doi.org/10.3201/eid3201.251261
AMA Probert WS, Kath C, Putirka N, et al. Dermacentor occidentalis Ticks and Link to Rickettsia lanei Infections, California, USA. Emerging Infectious Diseases. 2026;32(1):122-125. doi:10.3201/eid3201.251261.
APA Probert, W. S., Kath, C., Putirka, N., Saunders, M., Bermudez, B., Cazas, M. I....Hacker, J. K. (2026). Dermacentor occidentalis Ticks and Link to Rickettsia lanei Infections, California, USA. Emerging Infectious Diseases, 32(1), 122-125. https://doi.org/10.3201/eid3201.251261.

Disseminated Nocardia ignorata Infection with Splenic and Brain Involvement in Patient with Large B-Cell Lymphoma [PDF - 1.40 MB - 3 pages]
S. Elbaz et al.

A 79-year-old man in the United States with large B-cell lymphoma and chronic obstructive pulmonary disease had disseminated Nocardia ignorata infection involving the brain and spleen. Despite antimicrobial therapy, he died from complications. This rare manifestation highlights the need to consider Nocardia in immunocompromised patients with central nervous system and abdominal lesions.

EID Elbaz S, Ismail M, Glassman S, Badr A, Dove E. Disseminated Nocardia ignorata Infection with Splenic and Brain Involvement in Patient with Large B-Cell Lymphoma. Emerg Infect Dis. 2026;32(1):126-128. https://doi.org/10.3201/eid3201.251546
AMA Elbaz S, Ismail M, Glassman S, et al. Disseminated Nocardia ignorata Infection with Splenic and Brain Involvement in Patient with Large B-Cell Lymphoma. Emerging Infectious Diseases. 2026;32(1):126-128. doi:10.3201/eid3201.251546.
APA Elbaz, S., Ismail, M., Glassman, S., Badr, A., & Dove, E. (2026). Disseminated Nocardia ignorata Infection with Splenic and Brain Involvement in Patient with Large B-Cell Lymphoma. Emerging Infectious Diseases, 32(1), 126-128. https://doi.org/10.3201/eid3201.251546.

Detection of Avian Influenza H5–Specific Antibodies by Chemiluminescent Assays [PDF - 691 KB - 4 pages]
A. Márquez et al.

We evaluated 2 electrochemiluminescence serologic assays to detect avian influenza H5 antibodies. The assays identified H5 antibodies from both serum and dried blood spots and had strong specificity and minimal cross-reactivity in human and avian samples. Such assays can support populationwide serologic surveys aimed at assessing population-level immunity.

EID Márquez A, Beitari S, Valadbeigy T, Hoang L, Berhane Y, Jassem AN. Detection of Avian Influenza H5–Specific Antibodies by Chemiluminescent Assays. Emerg Infect Dis. 2026;32(1):129-132. https://doi.org/10.3201/eid3201.251117
AMA Márquez A, Beitari S, Valadbeigy T, et al. Detection of Avian Influenza H5–Specific Antibodies by Chemiluminescent Assays. Emerging Infectious Diseases. 2026;32(1):129-132. doi:10.3201/eid3201.251117.
APA Márquez, A., Beitari, S., Valadbeigy, T., Hoang, L., Berhane, Y., & Jassem, A. N. (2026). Detection of Avian Influenza H5–Specific Antibodies by Chemiluminescent Assays. Emerging Infectious Diseases, 32(1), 129-132. https://doi.org/10.3201/eid3201.251117.

Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina [PDF - 1.61 MB - 4 pages]
B. Filoni et al.

During 2023–2024, we detected rat hepatitis E virus in 67.7% of wastewater samples from central Argentina. This high level of detection opens new inquiries in the region, highlighting the need to investigate the virus in both animal reservoirs and humans, with a focus on hepatitis cases of unknown etiology.

EID Filoni B, Lucero M, Di Cola G, Fantilli A, Roccia A, Sicilia P, et al. Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina. Emerg Infect Dis. 2026;32(1):133-136. https://doi.org/10.3201/eid3201.251218
AMA Filoni B, Lucero M, Di Cola G, et al. Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina. Emerging Infectious Diseases. 2026;32(1):133-136. doi:10.3201/eid3201.251218.
APA Filoni, B., Lucero, M., Di Cola, G., Fantilli, A., Roccia, A., Sicilia, P....Pisano, M. (2026). Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina. Emerging Infectious Diseases, 32(1), 133-136. https://doi.org/10.3201/eid3201.251218.

Presence or Emergence of Canine Leishmaniasis, Malawi [PDF - 1.71 MB - 5 pages]
B. Chikufenji et al.

Canine leishmaniasis has long been thought to be absent in Malawi. However, our cross-sectional study in indigenous dogs showed a high prevalence of Leishmania infection in some areas, where seropositivity rates reached up to 7.0%. These findings suggest that this neglected zoonotic disease may already be endemic in Malawi.

EID Chikufenji B, Hayashida K, Goto Y, Sugi T, Sanjoba C, Njala C, et al. Presence or Emergence of Canine Leishmaniasis, Malawi. Emerg Infect Dis. 2026;32(1):137-141. https://doi.org/10.3201/eid3201.250855
AMA Chikufenji B, Hayashida K, Goto Y, et al. Presence or Emergence of Canine Leishmaniasis, Malawi. Emerging Infectious Diseases. 2026;32(1):137-141. doi:10.3201/eid3201.250855.
APA Chikufenji, B., Hayashida, K., Goto, Y., Sugi, T., Sanjoba, C., Njala, C....Chatanga, E. (2026). Presence or Emergence of Canine Leishmaniasis, Malawi. Emerging Infectious Diseases, 32(1), 137-141. https://doi.org/10.3201/eid3201.250855.

Tularemia in New York, USA, 1993–2023 [PDF - 960 KB - 4 pages]
D. T. Gaber et al.

During 1993–2023, health officials in New York, USA, received reports of 30 tularemia cases. Of those, 43% were from Suffolk County, 69% were diagnosed during 2014–2023, and 1 person died. Tick surveillance detected Francisella tularensis in 1 pool of nymphs from Suffolk County, indicating localized risk.

EID Gaber DT, Prusinski MA, Hodge A, White A, Santoriello MP, Romano CL, et al. Tularemia in New York, USA, 1993–2023. Emerg Infect Dis. 2026;32(1):142-145. https://doi.org/10.3201/eid3201.250854
AMA Gaber DT, Prusinski MA, Hodge A, et al. Tularemia in New York, USA, 1993–2023. Emerging Infectious Diseases. 2026;32(1):142-145. doi:10.3201/eid3201.250854.
APA Gaber, D. T., Prusinski, M. A., Hodge, A., White, A., Santoriello, M. P., Romano, C. L....White, J. L. (2026). Tularemia in New York, USA, 1993–2023. Emerging Infectious Diseases, 32(1), 142-145. https://doi.org/10.3201/eid3201.250854.
Research Letters

Mycobacterium decipiens Infection in Patient Receiving Anti–TNF-α Therapy, France, 2024 [PDF - 592 KB - 3 pages]
J. Destoop et al.

Mycobacterium decipiens is a newly identified species with high genomic similarity to M. tuberculosis. We report a cutaneous M. decipiens infection in a patient in France who had inflammatory bowel disease being treated with anti–tumor necrosis factor-α therapy. The infection was successfully treated with an oral antimicrobial regimen.

EID Destoop J, Poignon C, Danjou W, Bleibtreu A, Pourcher V, Monsel G. Mycobacterium decipiens Infection in Patient Receiving Anti–TNF-α Therapy, France, 2024. Emerg Infect Dis. 2026;32(1):146-148. https://doi.org/10.3201/eid3201.250518
AMA Destoop J, Poignon C, Danjou W, et al. Mycobacterium decipiens Infection in Patient Receiving Anti–TNF-α Therapy, France, 2024. Emerging Infectious Diseases. 2026;32(1):146-148. doi:10.3201/eid3201.250518.
APA Destoop, J., Poignon, C., Danjou, W., Bleibtreu, A., Pourcher, V., & Monsel, G. (2026). Mycobacterium decipiens Infection in Patient Receiving Anti–TNF-α Therapy, France, 2024. Emerging Infectious Diseases, 32(1), 146-148. https://doi.org/10.3201/eid3201.250518.

Fatal Ehrlichia muris eauclairensis Infection in Liver Transplant Recipient, Minnesota, USA [PDF - 1.40 MB - 3 pages]
S. Sahra et al.

Ehrlichia muris eauclairensis bacterial infections can manifest with atypical and severe symptoms in immunocompromised patients. We report a fatal case of severe ehrlichiosis caused by E. muris eauclairensis in a liver transplant recipient in Minnesota, USA. Healthcare providers must remain vigilant about tickborne infections in endemic regions, especially among immunocompromised patients.

EID Sahra S, Chesdachai S, Vergidis P, Sanchez W, Pritt BS. Fatal Ehrlichia muris eauclairensis Infection in Liver Transplant Recipient, Minnesota, USA. Emerg Infect Dis. 2026;32(1):148-150. https://doi.org/10.3201/eid3201.250893
AMA Sahra S, Chesdachai S, Vergidis P, et al. Fatal Ehrlichia muris eauclairensis Infection in Liver Transplant Recipient, Minnesota, USA. Emerging Infectious Diseases. 2026;32(1):148-150. doi:10.3201/eid3201.250893.
APA Sahra, S., Chesdachai, S., Vergidis, P., Sanchez, W., & Pritt, B. S. (2026). Fatal Ehrlichia muris eauclairensis Infection in Liver Transplant Recipient, Minnesota, USA. Emerging Infectious Diseases, 32(1), 148-150. https://doi.org/10.3201/eid3201.250893.

Molecular Analysis of Emerging MT27 Macrolide-Resistant Bordetella pertussis, Kobe, Japan, 2025 [PDF - 525 KB - 4 pages]
S. Komatsu et al.

We report the emergence and spread of multilocus variable-number tandem-repeat analysis type 27 (MT-27) macrolide-resistant Bordetella pertussis (MRBP) in Kobe, Japan, in 2025. Whole-genome sequencing revealed that MT27-MRBP did not originate from the widely circulating MT27 macrolide-sensitive B. pertussis in Japan but was closely related to MRBP in China.

EID Komatsu S, Nakanishi N, Matsubara K, Inenaga Y, Hori M, Shiotani K, et al. Molecular Analysis of Emerging MT27 Macrolide-Resistant Bordetella pertussis, Kobe, Japan, 2025. Emerg Infect Dis. 2026;32(1):150-153. https://doi.org/10.3201/eid3201.250890
AMA Komatsu S, Nakanishi N, Matsubara K, et al. Molecular Analysis of Emerging MT27 Macrolide-Resistant Bordetella pertussis, Kobe, Japan, 2025. Emerging Infectious Diseases. 2026;32(1):150-153. doi:10.3201/eid3201.250890.
APA Komatsu, S., Nakanishi, N., Matsubara, K., Inenaga, Y., Hori, M., Shiotani, K....Kusunoki, N. (2026). Molecular Analysis of Emerging MT27 Macrolide-Resistant Bordetella pertussis, Kobe, Japan, 2025. Emerging Infectious Diseases, 32(1), 150-153. https://doi.org/10.3201/eid3201.250890.

Donor Screening Failure for Strongyloides stercoralis in Solid Organ Transplantation [PDF - 876 KB - 3 pages]
R. Kohan et al.

We report 2 cases of donor-derived Strongyloides stercoralis infection in renal transplant recipients. Despite initial negative serologic testing in donor samples, retrospective testing confirmed transmission. This report underscores the limitations of serologic screening, the need for targeted protocols in endemic-risk populations, and the importance of close posttransplant surveillance.

EID Kohan R, Gil-Campesino H, García Rodríguez IO, Lara M. Donor Screening Failure for Strongyloides stercoralis in Solid Organ Transplantation. Emerg Infect Dis. 2026;32(1):153-155. https://doi.org/10.3201/eid3201.251483
AMA Kohan R, Gil-Campesino H, García Rodríguez IO, et al. Donor Screening Failure for Strongyloides stercoralis in Solid Organ Transplantation. Emerging Infectious Diseases. 2026;32(1):153-155. doi:10.3201/eid3201.251483.
APA Kohan, R., Gil-Campesino, H., García Rodríguez, I. O., & Lara, M. (2026). Donor Screening Failure for Strongyloides stercoralis in Solid Organ Transplantation. Emerging Infectious Diseases, 32(1), 153-155. https://doi.org/10.3201/eid3201.251483.

Serologic Evidence of Exposure to Burkholderia pseudomallei, Nigeria [PDF - 750 KB - 3 pages]
J. Savelkoel et al.

Melioidosis is an underreported cause of community-acquired pneumonia and sepsis in Nigeria. We conducted a cross-sectional study using a Burkholderia pseudomallei protein microarray in 500 healthy participants from Nigeria. We observed a serologic response supportive of past exposure to the causative agent of melioidosis in 30% of study participants.

EID Savelkoel J, Wagner GE, Ojide CK, Frankenfeld K, Rudloff A, Dunachie SJ, et al. Serologic Evidence of Exposure to Burkholderia pseudomallei, Nigeria. Emerg Infect Dis. 2026;32(1):156-158. https://doi.org/10.3201/eid3201.251113
AMA Savelkoel J, Wagner GE, Ojide CK, et al. Serologic Evidence of Exposure to Burkholderia pseudomallei, Nigeria. Emerging Infectious Diseases. 2026;32(1):156-158. doi:10.3201/eid3201.251113.
APA Savelkoel, J., Wagner, G. E., Ojide, C. K., Frankenfeld, K., Rudloff, A., Dunachie, S. J....Oladele, R. O. (2026). Serologic Evidence of Exposure to Burkholderia pseudomallei, Nigeria. Emerging Infectious Diseases, 32(1), 156-158. https://doi.org/10.3201/eid3201.251113.

Localized Outbreak of Macrolide-Resistant Pertussis in Infants, Japan, March–May 2025 [PDF - 558 KB - 4 pages]
T. Obara et al.

A localized pertussis outbreak involving 10 unvaccinated infants occurred in Kumamoto, Japan, during March–May 2025. Nine infants were admitted to the pediatric intensive care unit, 6 of whom received a confirmed diagnosis of macrolide-resistant Bordetella pertussis infection. This outbreak highlights the importance of booster vaccinations and resistance surveillance.

EID Obara T, Kano K, Yorifuji T, Tsukahara K, Yogo N, Muto Y, et al. Localized Outbreak of Macrolide-Resistant Pertussis in Infants, Japan, March–May 2025. Emerg Infect Dis. 2026;32(1):158-161. https://doi.org/10.3201/eid3201.250824
AMA Obara T, Kano K, Yorifuji T, et al. Localized Outbreak of Macrolide-Resistant Pertussis in Infants, Japan, March–May 2025. Emerging Infectious Diseases. 2026;32(1):158-161. doi:10.3201/eid3201.250824.
APA Obara, T., Kano, K., Yorifuji, T., Tsukahara, K., Yogo, N., Muto, Y....Hirai, K. (2026). Localized Outbreak of Macrolide-Resistant Pertussis in Infants, Japan, March–May 2025. Emerging Infectious Diseases, 32(1), 158-161. https://doi.org/10.3201/eid3201.250824.
Online Reports

Integrating Prevention and Response at the Crossroads of Henipavirus Preparedness, Hendra@30 Conference, 2024 [PDF - 308 KB - 7 pages]
K. Halpin et al.

Diseases caused by henipaviruses, exemplified by Hendra virus and Nipah virus, pose a serious risk to public health because of their epidemic potential and high case-fatality rates and the paucity of medical countermeasures to mitigate them. In December 2024, a group of 150 scientists from 16 countries convened in Geelong, Victoria, Australia, to mark the 30th anniversary of the discovery of Hendra virus. The Hendra@30 conference built upon its predecessor conference held in 2019 in Singapore, Nipah@20, by expanding its program across broader disciplines and integrating sessions on human sociology and disease ecology into the main scientific discussions. We describe key highlights from Hendra@30 and reflect on 4 key elements that have advanced henipavirus research and medical countermeasures research and development. We propose that integrating bat ecology into henipavirus research blueprints will enable development of ecologic countermeasures that prevent spillover and will complement existing preparedness and response efforts with evidence-based prevention strategies.

EID Halpin K, Román R, de Wit E, Peel AJ, Epstein JH, Barr J, et al. Integrating Prevention and Response at the Crossroads of Henipavirus Preparedness, Hendra@30 Conference, 2024. Emerg Infect Dis. 2026;32(1):1-7. https://doi.org/10.3201/eid3201.250979
AMA Halpin K, Román R, de Wit E, et al. Integrating Prevention and Response at the Crossroads of Henipavirus Preparedness, Hendra@30 Conference, 2024. Emerging Infectious Diseases. 2026;32(1):1-7. doi:10.3201/eid3201.250979.
APA Halpin, K., Román, R., de Wit, E., Peel, A. J., Epstein, J. H., Barr, J....Markotter, W. (2026). Integrating Prevention and Response at the Crossroads of Henipavirus Preparedness, Hendra@30 Conference, 2024. Emerging Infectious Diseases, 32(1), 1-7. https://doi.org/10.3201/eid3201.250979.
About the Cover

Nocardia and the Death of Raphael (1520) [PDF - 2.07 MB - 3 pages]
P. Charlier et al.
EID Charlier P, Héry-Arnaud G, Kofoed K, Armengaud J. Nocardia and the Death of Raphael (1520). Emerg Infect Dis. 2026;32(1):162-164. https://doi.org/10.3201/eid3201.ac3201
AMA Charlier P, Héry-Arnaud G, Kofoed K, et al. Nocardia and the Death of Raphael (1520). Emerging Infectious Diseases. 2026;32(1):162-164. doi:10.3201/eid3201.ac3201.
APA Charlier, P., Héry-Arnaud, G., Kofoed, K., & Armengaud, J. (2026). Nocardia and the Death of Raphael (1520). Emerging Infectious Diseases, 32(1), 162-164. https://doi.org/10.3201/eid3201.ac3201.
Page created: January 21, 2026
Page updated: January 29, 2026
Page reviewed: January 29, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
edit_01 ScholarOne Submission Portal
Issue Select
GO
GO

Spotlight Topics

 

 

Get Email Updates

To receive email updates about this page, enter your email address:

file_external